QureBio
↗Shanghai, China
QureBio is a clinical-stage biotechnology company founded in 2017 and headquartered in Shanghai's Zhangjiang Hi-Tech Park. The company specializes in the discovery and development of innovative antibody-based therapeutics, with a core focus on bispecific and multispecific antibodies for the treatment of refractory cancers, autoimmune diseases, and inflammatory disorders.
QureBio leverages several proprietary technology platforms, including its I2T platform and specialized T-cell and NK-cell engager platforms, to engineer complex biologics with enhanced efficacy and safety profiles. The company's lead candidate, Q-1802, is a first-in-class bispecific antibody targeting Claudin 18.2 and PD-L1, currently in Phase II clinical trials with promising data in gastric and gastrointestinal cancers.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:Pre-revenue
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series C1
Total Raised:$45M+
Investors:Efung Capital, Advantech Capital, Oriza Seed, Shenzhen Capital Group (SCGC), Viva Bio-Innovator, Jundu Investment, Watson Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (Q-1802)
Modalities:mAb, Bispecific antibody, Multispecific antibody, Antibody-cytokine fusion
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:BRL Medicine (CAR-T collaboration), BioMap (AI-driven target discovery), Hengrui Pharma (Co-development), Precision Scientific
COMPETITION
Position:Emerging
Competitors:Amgen, Astellas Pharma, Innovent Biologics, Akeso, Legend Biotech
LEADERSHIP
Key Executives:
Xiangdong Qu - Founder & CEO
Yejie Du - Deputy General Manager
Qiying Lu - Chief Medical Officer
Scientific Founders:Xiangdong Qu
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with QureBio. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.